Geron Corp at Needham Healthcare Conference (Virtual) Transcript
Good morning, everyone, and thank you for joining us at the fourth day of the Needham & Company healthcare conference. My name is Gil Bloom, and I'm a senior biotech analyst here at Needham & Company covering the immuno-oncology and gene therapy subsectors.
It is my pleasure to have with me today Chip Scarlett, the CEO of Geron. So as a reminder, any viewers who are watching through our conference portal are able to submit a question through the ask-a-question box below the video feed window.
So Chip, you said you were going to have some comments ahead. I will give you the stage.
Okay, great. Well, first, I have to do the forward-looking statement here. So if you would pop that up, Olivia, thanks.
So during the course of this chat will be forward-looking statements regarding future events, performance, plans, expectations, and other projections including those relating to the therapeutic potential
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |